SELLAS Life Sciences Group, Inc. (SLS)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$107.2M
Cash & Equivalents
$8.9M
Quarterly Burn Rate
36 mo
Est. Cash Runway
$1,596M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for SLS.

SEC EDGAR Filings

All SEC filings for SELLAS Life Sciences Group, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.